Whales with a lot of money to spend have taken a noticeably bearish stance on Apellis Pharmaceuticals.
Looking at options history for Apellis Pharmaceuticals APLS we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 7% of the investors opened trades with bullish expectations and 92% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $90,630 and 11, calls, for a total amount of $1,684,106.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $75.0 for Apellis Pharmaceuticals over the last 3 months.
Volume & Open Interest Development
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Apellis Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apellis Pharmaceuticals's whale activity within a strike price range from $40.0 to $75.0 in the last 30 days.
Apellis Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APLS | CALL | SWEEP | BEARISH | 01/17/25 | $6.3 | $4.8 | $5.1 | $60.00 | $604.8K | 133 | 1 |
| APLS | CALL | SWEEP | BEARISH | 10/18/24 | $5.6 | $3.0 | $3.3 | $60.00 | $404.1K | 5 | 1.0K |
| APLS | CALL | TRADE | BEARISH | 10/18/24 | $3.0 | $2.75 | $2.75 | $70.00 | $275.0K | 1.0K | 0 |
| APLS | CALL | TRADE | NEUTRAL | 06/21/24 | $10.0 | $8.9 | $9.4 | $40.00 | $94.0K | 199 | 100 |
| APLS | PUT | SWEEP | BEARISH | 05/17/24 | $2.95 | $2.9 | $2.95 | $45.00 | $63.1K | 1.3K | 0 |
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
In light of the recent options history for Apellis Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Apellis Pharmaceuticals's Current Market Status
- With a volume of 756,695, the price of APLS is down -1.04% at $47.53.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 14 days.
Professional Analyst Ratings for Apellis Pharmaceuticals
In the last month, 4 experts released ratings on this stock with an average target price of $73.5.
- Maintaining their stance, an analyst from Wedbush continues to hold a Neutral rating for Apellis Pharmaceuticals, targeting a price of $57.
- Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $92.
- Consistent in their evaluation, an analyst from Mizuho keeps a Neutral rating on Apellis Pharmaceuticals with a target price of $60.
- In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $85.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apellis Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
